Clinico-pathological factors predicting pathological response in early triple-negative breast cancer

Pathological complete response (pCR) after neoadjuvant chemoimmunotherapy (NACi) is associated with improved patient outcomes in early triple-negative breast cancer (TNBC). This study aimed to identify factors associated with pCR after NACi. This cohort included all patients with stage II-III TNBC treated with NACi who underwent surgery at Institut Curie hospitals between 08/2021-06/2023. Among 208 patients, the overall pCR rate was 70% and was similar in ER < 1% (69%) and ER-low TNBC (73%, p = 0.6). In a multivariate model, Ki-67 ≥ 30% (OR 5.19 [1.73-17.3]), centralized TILs ≥ 30% (OR = 3.08 [1.42-7.04]), absence of DCIS at initial biopsy (OR = 2.56 [1.08-6.25]) and germline mutations in homologous recombination genes (OR = 9.50 [2.37-67.7]) remained strong independent predictors of pCR. These findings may guide treatment decisions in patients with TNBC undergoing NACi. Almost all patients with germline mutations in HR genes achieved pCR, supporting de-escalation trials. We suggest that ER-low tumors should be managed as TNBC tumors.

Authors

Institutions

Publication Details

Journal
npj Breast Cancer
Published
2025-02-13
DOI
https://doi.org/10.1038/s41523-025-00729-8
Citations
20
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
18.72

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinico-pathological factors predicting pathological response in early triple-negative breast cancer

Toulsie Ramtohul, François‐Clément Bidard, Emanuela Romano, Matthieu Carton et al.
20 citations
npj Breast Cancer
Breast Cancer Treatment Studies
18.72
article

Clinico-pathological factors predicting pathological response in early triple-negative breast cancer

Toulsie Ramtohul, François‐Clément Bidard, Emanuela Romano, Matthieu Carton, Paul Henri Cottu, Enora Laas, Anne Vincent‐Salomon, Ivan Bièche, Clara Helal, Claire Bonneau, Romain‐David Seban, Luc Cabel, Nicolas Kiavué, Diana Bello-Roufai, Lounes Djerroudi, Delphine Loirat, Maxime Jin, Florence Lerebours
article en
20 citations

Abstract

Pathological complete response (pCR) after neoadjuvant chemoimmunotherapy (NACi) is associated with improved patient outcomes in early triple-negative breast cancer (TNBC). This study aimed to identify factors associated with pCR after NACi. This cohort included all patients with stage II-III TNBC treated with NACi who underwent surgery at Institut Curie hospitals between 08/2021-06/2023. Among 208 patients, the overall pCR rate was 70% and was similar in ER < 1% (69%) and ER-low TNBC (73%, p = 0.6). In a multivariate model, Ki-67 ≥ 30% (OR 5.19 [1.73-17.3]), centralized TILs ≥ 30% (OR = 3.08 [1.42-7.04]), absence of DCIS at initial biopsy (OR = 2.56 [1.08-6.25]) and germline mutations in homologous recombination genes (OR = 9.50 [2.37-67.7]) remained strong independent predictors of pCR. These findings may guide treatment decisions in patients with TNBC undergoing NACi. Almost all patients with germline mutations in HR genes achieved pCR, supporting de-escalation trials. We suggest that ER-low tumors should be managed as TNBC tumors.

npj Breast CancerVol. 11(1)
Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Cité (FR), Université Paris Sciences et Lettres (FR), Université Paris-Saclay (FR), St. Cloud Hospital (US), Institut Curie (FR)
Agence Nationale de la Recherche
Good health and well-being
Openalex Percentile: Top 1%
Breast Cancer Treatment Studies
18.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.